Free Trial

Longboard Pharmaceuticals (LBPH) Competitors

$18.87
+0.97 (+5.42%)
(As of 05/31/2024 ET)

LBPH vs. SCTL, ARWR, IDYA, PTCT, MOR, DYN, JANX, MLTX, TGTX, and RNA

Should you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Societal CDMO (SCTL), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), PTC Therapeutics (PTCT), MorphoSys (MOR), Dyne Therapeutics (DYN), Janux Therapeutics (JANX), MoonLake Immunotherapeutics (MLTX), TG Therapeutics (TGTX), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical preparations" industry.

Longboard Pharmaceuticals vs.

Societal CDMO (NASDAQ:SCTL) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.

Societal CDMO has higher revenue and earnings than Longboard Pharmaceuticals. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Societal CDMO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Societal CDMO$94.64M1.23-$13.27M-$0.15-7.33
Longboard PharmaceuticalsN/AN/A-$54.42M-$2.24-8.42

Longboard Pharmaceuticals received 36 more outperform votes than Societal CDMO when rated by MarketBeat users. However, 80.00% of users gave Societal CDMO an outperform vote while only 73.33% of users gave Longboard Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Societal CDMOOutperform Votes
8
80.00%
Underperform Votes
2
20.00%
Longboard PharmaceuticalsOutperform Votes
44
73.33%
Underperform Votes
16
26.67%

In the previous week, Longboard Pharmaceuticals had 4 more articles in the media than Societal CDMO. MarketBeat recorded 4 mentions for Longboard Pharmaceuticals and 0 mentions for Societal CDMO. Societal CDMO's average media sentiment score of 0.87 beat Longboard Pharmaceuticals' score of 0.00 indicating that Longboard Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Societal CDMO Neutral
Longboard Pharmaceuticals Positive

Societal CDMO has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

87.2% of Societal CDMO shares are held by institutional investors. Comparatively, 63.3% of Longboard Pharmaceuticals shares are held by institutional investors. 7.6% of Societal CDMO shares are held by company insiders. Comparatively, 4.6% of Longboard Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Longboard Pharmaceuticals has a net margin of 0.00% compared to Longboard Pharmaceuticals' net margin of -14.03%. Longboard Pharmaceuticals' return on equity of -23.82% beat Societal CDMO's return on equity.

Company Net Margins Return on Equity Return on Assets
Societal CDMO-14.03% -23.82% -8.80%
Longboard Pharmaceuticals N/A -49.87%-46.04%

Societal CDMO currently has a consensus price target of $1.80, indicating a potential upside of 63.64%. Longboard Pharmaceuticals has a consensus price target of $43.67, indicating a potential upside of 131.41%. Given Societal CDMO's stronger consensus rating and higher possible upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Societal CDMO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Societal CDMO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Longboard Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Societal CDMO beats Longboard Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LBPH vs. The Competition

MetricLongboard PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$733.67M$6.78B$5.17B$7.99B
Dividend YieldN/A2.65%2.76%4.00%
P/E Ratio-8.4214.07112.9316.35
Price / SalesN/A276.472,390.4976.60
Price / CashN/A32.7035.4931.55
Price / Book2.346.085.544.59
Net Income-$54.42M$138.60M$106.07M$213.90M
7 Day Performance0.37%3.29%1.15%0.87%
1 Month Performance-17.27%0.05%0.65%1.82%
1 Year Performance162.45%-3.68%2.70%5.90%

Longboard Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCTL
Societal CDMO
0 of 5 stars
$1.10
+0.9%
$1.80
+63.6%
+50.5%$116.26M$94.64M-7.33258
ARWR
Arrowhead Pharmaceuticals
4.109 of 5 stars
$22.87
+0.4%
$51.00
+123.0%
-33.8%$2.84B$240.74M-5.38525Positive News
IDYA
IDEAYA Biosciences
3.4437 of 5 stars
$37.07
+3.6%
$46.80
+26.2%
+52.8%$2.81B$23.39M-18.44124Insider Selling
News Coverage
PTCT
PTC Therapeutics
3.1347 of 5 stars
$36.21
+1.1%
$35.67
-1.5%
-16.4%$2.78B$937.82M-4.71988Analyst Forecast
MOR
MorphoSys
0.0727 of 5 stars
$18.32
-0.2%
$11.78
-35.7%
+189.2%$2.76B$257.89M-5.26524Short Interest ↑
DYN
Dyne Therapeutics
3.8213 of 5 stars
$31.35
+0.5%
$40.78
+30.1%
+149.3%$2.74BN/A-7.90143Analyst Revision
JANX
Janux Therapeutics
2.5417 of 5 stars
$52.81
+4.8%
$66.29
+25.5%
+342.1%$2.74B$8.08M-43.2968Analyst Forecast
MLTX
MoonLake Immunotherapeutics
1.0593 of 5 stars
$41.43
+1.0%
$74.46
+79.7%
+47.6%$2.65BN/A-55.2450Positive News
TGTX
TG Therapeutics
4.1646 of 5 stars
$16.72
-1.0%
$29.83
+78.4%
-40.5%$2.58B$233.66M72.70284Positive News
RNA
Avidity Biosciences
1.6822 of 5 stars
$26.85
-0.8%
$41.33
+53.9%
+147.1%$2.57B$9.56M-9.10253Positive News

Related Companies and Tools

This page (NASDAQ:LBPH) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners